DOCSLIB.ORG

Protecting the Aged Heart During Cardiac Surgery: Use of Del Nido Cardioplegia Provides Superior Functional Recovery in Isolated Hearts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Protecting the Aged Heart During Cardiac Surgery: Use of Del Nido Cardioplegia Provides Superior Functional Recovery in Isolated Hearts View metadata, citation and similar papers at core.ac.uk brought to you by CORE EVOLVING TECHNOLOGY/BASIC SCIENCE provided by Elsevier - Publisher Connector Protecting the aged heart during cardiac surgery: Use of del Nido cardioplegia provides superior functional recovery in isolated hearts Arun Govindapillai, BSc,a Rui Hua, PhD,a Robert Rose, PhD,a Camille Hancock Friesen, MD,b,c,d and Stacy B. O’Blenes, MDa,b,c Objectives: Aged hearts are particularly vulnerable to ischemia-reperfusion injury. Our objective was to determine if del Nido cardioplegia, which contains lidocaine, less blood, and less calcium than our standard cardioplegia, provides superior protection for aged hearts. We also sought to determine if the lidocaine in del Nido cardioplegia is adequate to prevent Naþ influx via the window current. Methods: Sodium channel kinetics were measured in rat cardiomyocytes with and without lidocaine. Recovery after 60 minutes of cardioplegic arrest was assessed in isolated working senescent rat hearts. Del Nido cardioplegia was delivered as a single dose (n ¼ 8) because it is used clinically, and standard cardioplegia was delivered as an induction dose with re-dosing every 20 minutes (n ¼ 8). After 20 minutes of reperfusion, hearts were switched to working mode for 60 minutes. Flows were indexed to ventricular dry weight. Troponin release was assayed. Results: Sodium channel kinetics indicated that the lidocaine concentration in del Nido cardioplegia minimizes the potential for Naþ influx via the window current. Spontaneous contractions occurred in fewer hearts arrested with del Nido cardioplegia (88% vs 13%; P ¼ .01), and troponin release was reduced (0.24 vs 0.89 ng/mL; P ¼ .017). Cardiac output was approximately 90% of baseline in the del Nido group compared with À À approximately 50% in the standard group (173 Æ 14 vs 86 Æ 22 mL $ min 1 $ g 1; P ¼ .0008). Stroke work was higher in the del Nido group (93 Æ 6vs41Æ 10 mL $ mm Hg $ gÀ1; P ¼ .0002). Conclusions: Del Nido cardioplegia prevents spontaneous contractions during arrest, reduces troponin release, and results in superior myocardial function in isolated aged hearts. Del Nido cardioplegia has the potential to provide superior myocardial protection for older patients undergoing cardiac surgery. (J Thorac Cardiovasc Surg 2013;146:940-8) The growing number of elderly patients requiring cardiac Ca2þ, and contains lidocaine (Table 1). Del Nido cardiople- surgery is an important group at higher risk for cardiac gia usually is given as a single dose,9-11 whereas our dysfunction and death postoperatively.1,2 Aged hearts are standard cardioplegia is given as an induction dose particularly susceptible to reperfusion injury after the followed by maintenance doses approximately every ischemic periods that occur during cardiac surgery3-5 20 minutes. The del Nido cardioplegia strategy results in owing to changes in the way cardiomyocytes deal with lower postoperative troponin release in pediatric patients intracellular Ca2þ, particularly during ischemia.5-8 compared with our standard cardioplegia.9 Del Nido cardioplegia is used in several centers for Because elderly myocardium is similar to immature myocardial protection during pediatric cardiac surgery.9-11 myocardium in that both are particularly susceptible to þ Compared with the standard 4:1 blood cardioplegia we reperfusion injury related to Ca2 overload,3-8,12-14 we use in our adult practice, del Nido cardioplegia is more hypothesized that a del Nido cardioplegia strategy also dilute (1:4 blood:crystalloid), has approximately 75% less may be beneficial in the elderly. We previously showed, in cardiomyocytes from aged rats (z24 mo), that arrest with del Nido cardioplegia results in less activity during From the Departments of Physiology and Biophysics,a Surgery,c Pathology,d Dalhou- 2þ b the ischemic period, lower diastolic Ca during ischemia sie University, and IWK Health Centre, Halifax, Nova Scotia, Canada. 2þ Supported by grants form the Canadian Institutes for Health Research and the Heart and reperfusion, and avoidance of Ca -induced 15 and Stroke Foundation of Nova Scotia. Robert Rose is supported by a Canadian hypercontraction during early reperfusion. The objective Institutes for Health Research New Investigator Award. of this study was to determine if the beneficial effects Disclosures: Authors have nothing to disclose with regard to commercial support. Read at the 93rd Annual Meeting of The American Association for Thoracic seen with del Nido cardioplegia in aged cardiomyocytes Surgery, Minneapolis, Minnesota, May 4-8, 2013. translate into improved functional recovery in elderly whole Received for publication April 18, 2013; revisions received May 16, 2013; accepted ET/BS hearts. for publication May 20, 2013; available ahead of print Aug 19, 2013. Address for reprints: Stacy B. O’Blenes, MD, IWK Children’s Heart Centre, IWK Sodium influx is thought to be the main cause of 2þ Health Centre, 5850/5980 University Ave, PO Box 9700, Halifax, Nova Scotia intracellular Ca accumulation during ischemia by B3K 6R8, Canada (E-mail: [email protected]). driving reverse-mode Naþ/Ca2þ exchange.16,17 During 0022-5223/$36.00 Ó hyperkalemic cardioplegic arrest, membrane depolarization Copyright 2013 by The American Association for Thoracic Surgery þ http://dx.doi.org/10.1016/j.jtcvs.2013.05.032 opens a proportion of the voltage-gated Na channels 940 The Journal of Thoracic and Cardiovascular Surgery c October 2013 Govindapillai et al Evolving Technology/Basic Science Mg-adenosine triphosphate 4 mmol/L, Na-phosphocreatine 6.6 mmol/L, Abbreviation and Acronym Na-guanosine triphosphate 0.3 mmol/L, and HEPES 10 mmol/L, pH 7.2. ¼ The resistance of the borosilicate glass micropipettes (1.5 mm outer INa sodium current diameter, 0.75 mm inner diameter) was 3 to 5 MU, seal resistance was 2 to 15 GU, and rupturing the sarcolemma in the patch for voltage clamp experiments resulted in access resistances of 5 to 15 MU. Series resistance % % spanning the cell membrane. Most of these channels are compensation averaged 80 to 85 using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, Calif). Data were digitized using a inactivated rapidly, thereby preventing action potential Digidata 1440 and pCLAMP 10 software (Molecular Devices). generation and propagation, but a small fraction remain The voltage clamp protocol for measuring I current-voltage relation- þ Na tonically available and allow Na to flow into the cell via a ships and activation kinetics consisted of holding myocytes at -100 mVand 18-20 À þ window current. Lidocaine used as an additive to then giving a series of 20-ms, 10-mV steps from 80 to 60 mv. INa depolarizing cardioplegia may limit Naþ influx by activation kinetics were determined by calculating chord conductance (G) using the following equation: G ¼ I/(V ÀE ), where V represents blocking the window current, however, this has not been m rev m the depolarizing voltages and Erev is the reversal potential estimated well described. We investigated whether the concentration from the current-voltage relation of INa. The protocol for measuring INa of lidocaine present in del Nido cardioplegia is adequate to inactivation consisted of holding myocytes at À140 mVand giving a series minimize the potential for Naþ influx via thewindow current. of 500-ms voltage-clamp conditioning steps from À120 mV to À20 mV followed by a 20-ms voltage clamp test step to À20 mV. Activation and inactivation curves were generated by fitting normalized data with a MATERIALS AND METHODS Boltzmann function to determine the V1/2 of activation (V1/2[act]), and Experimental Animals and Anesthesia inactivation (V1/2[inact]) in the presence and absence (control) of lidocaine Experiments were performed in accordance with guidelines published 0.36 mmol/L, as found in del Nido cardioplegia. by the Canadian Council on Animal Care.21 Male Fisher 344 rats (3-4 mo for isolated cardiomyocyte studies, and 23-24 mo for isolated heart Isolated Working Heart studies) obtained from Charles River Laboratories (Saint-Constant, Hearts were cannulated via the aorta and pulmonary vein on a working Canada) were heparinized (intraperitoneally, 3000 U/kg; Pharmaceutical heart apparatus (Radnoti, Inc, Monrovia, Calif), and perfused retrograde Partners of Canada, Richmond, Ontario, Canada), and anesthetized with with Krebs-Henseleit buffer at 10 mL/min (37C). A temperature probe sodium pentobarbital (intraperitoneally, 160 mg/kg; Veterinary Medication and electrocardiogram electrode were placed through the pulmonary artery Distribution Centre; Saint-Hyacinthe, Quebec, Canada). Hearts were into the right ventricular outflow tract. Left atrial and aortic pressure and removed rapidly and placed in ice-cold Tyrode’s solution for isolated aortic flow (Transonic Systems, Inc, Ithaca, NY) were monitored cardiomyocyte studies (NaCl 140 mmol/L, KCl 5.4 mmol/L, Na HPO 1 2 4 continually using a PowerLab data acquisition system (ADI Instruments, mmol/L, CaCl 1 mmol/L, MgCl 1 mmol/L, glucose 10 mmol/L, HEPES 2 2 Colorado Springs, Colo). Coronary flow was measured by timed collection 5 mmol/L, pH 7.4), or Krebs-Henseleit buffer for isolated heart studies of effluent. After a 5-minute stabilization period, hearts were switched to (NaCl 118 mmol/L, KCl 4.71 mmol/L, NaHCO 25.0 mmol/L, KH PO 3 2 4 constant pressure mode (100 cm H O) for 5 minutes, and then into working 1.20 mmol/L, CaCl 2.50 mmol/L, MgSO 1.20 mmol/L, glucose 11 2 2 4 heart mode for 5 minutes (preload, 20 cm H O; afterload, 100 cm H O). mmol/L, ethylenediaminetetraacetic acid 0.5 mmol/L, equilibrated with 2 2 Only hearts that met the following predetermined baseline criteria were 95% O /5% CO , pH 7.4). 2 2 used in this study: heart rate greater than 200 bpm, regular rhythm, cardiac output greater than 25 mL/min, and coronary flow greater than 10 mL/ Cardiac Myocyte Isolation min.22 After the baseline working heart period, hearts were arrested with Ventricular cardiomyocytes were obtained by enzymatic dissociation.
Load more

Recommended publications
  • Myocardiial Protection Strategy Utilizing Retrograde Cardioplegia
    Myocardial Protection Strategy Utilizing Retrograde Cardioplegia Item Type text; Electronic Thesis Authors Karbasi, Michael Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the College of Medicine - Phoenix, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 25/09/2021 11:23:01 Link to Item http://hdl.handle.net/10150/281195 Myocardial Protection Strategy Utilizing Retrograde Cardioplegia for Neonatal Arterial Switch Operations Michael Karbasi1, John Nigro, M.D.2,3, Bradford Sanders, CCP,, MS2,3, Cyrus Kosar, MS4, Brigham C. Willis, M.D.1,2,3 1 University of Arizona, College of Medicine-Phoenix; 2Children’s Heart Center, Phoenix Children’s Hospital, Phoenix, AZ; 3Eller Congenital Heart Center at St. Joseph’s Hospital and Medical Center, Phoenix, AZ; and 4Institute for Aging Research in Affiliation with Harvard Medical School ABSTRACT RESULTS 30.0 Introduction: Myocardial protection strategies are a central component of neonatal arterial switch operations. Traditionally antegrade cardioplegia 25.0 through the aortic root has been the method of delivery, but use of retrograde cardioplegia via the coronary sinus has become the standard 20.0 of practice by many in the field. Methods: After obtaining IRB approval 15.0 Retrograde and informed consent, a retrospective chart review was done to assess Days Antegrade outcomes between 48 patients receiving antegrade (n= 5) and retrograde 10.0 (n= 43) cardioplegia during neonatal switch operations. Preoperative demographics and postoperative outcomes were compared between the 5.0 two groups and compared with historical studies.
    [Show full text]
  • Comparison of Del Nido Cardioplegia
    ORIGINAL ARTICLE Braz J Cardiovasc Surg 2021;36(2):158-64 Comparison of Del Nido Cardioplegia and Blood Cardioplegia in Terms of Development of Postoperative Atrial Fibrillation in Patients Undergoing Isolated Coronary Artery Bypass Grafting Umut Serhat Sanrı1, MD; Kadir Kaan Özsin1, MD; Faruk Toktaş1, MD; Şenol Yavuz1, MD DOI: 10.21470/1678-9741-2020-0047 Abstract length of hospital stay remain significantly higher in the BC group Objective: Del Nido cardioplegia (DNC) has been used in (P=0.044, P<0.001, respectively). In addition, the aortic cross-clamp pediatric cardiac surgery for many years with a single dose time and the cardioplegia volume delivered were significantly application and its usage in adult cardiac surgery has been lower in the DNC group (P=0.042, P<0.001, respectively). In increasing in recent years, with results being published. In multivariate logistic regression analysis, only higher cardioplegia this study, we aimed to investigate the effect of DNC on the volume was determined as an independent predictor for PoAF development of postoperative atrial fibrillation (PoAF). development (OR 1.001; 95% CI 1.000-1.001; P=0.033). We did not Methods: In this retrospective observational comparative found difference between groups in terms of troponin T, inotropic study, 255 patients who underwent isolated on-pump coronary drug support, need for intraaortic balloon pump and mortality. artery bypass grafting, between January 2019 and November Conclusion: This study showed that DNC can be used safely 2019, were enrolled. The patients were divided into two groups: in adult coronary bypass surgery and PoAF development effect DNC (n=132) and blood cardioplegia (BC) (n=123).
    [Show full text]
  • A Common Occurrence After Coronary Bypass Surgery
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector lACC Vol. 15, No.6 1261 May 1990:1261-9 Acute Myocardial Dysfunction and Recovery: A Common Occurrence After Coronary Bypass Surgery WARREN M. BREISBLATT, MD, FACC, KEITH L. STEIN, MD, CYNTHIA J. WOLFE, RN, WILLIAM P. FOLLANSBEE, MD, FACC, JOHN CAPOZZI, CNMT, JOHN M. ARMITAGE, MD, ROBERT L. HARDESTY, MD, FACC Pittsburgh, Pennsylvania To evaluate whether acute myocardial dysfunction was min after coronary bypass and showed complete recovery common in the early postoperative period, serial hemody• within 48 h. Left ventricular end-systolic and end-diastolic namic measurements and radionuclide evaluation of ven• volume index increased significantly postoperatively, but tricular function were performed before and after opera• recovery in left ventricular ejection fraction was mostly due tion in 24 patients undergoing elective coronary bypass to decreases in end-systolic volume index (50 ± 22 ml at surgery. All patients had uncomplicated surgery, and no trough and 32 ± 16 ml at recovery). Depressed myocardial patient sustained an intraoperative infarction. In 96% of function was independent of bypass time, number of grafts patients, significant depression in right and left ventricular placed, preoperative medications or core temperatures ejection fraction was seen postoperatively, reaching a nadir postoperatively. Postoperative therapy with pressors or at 262 ± 116 min after coronary bypass. Left ventricular inotropic agents delayed but did
    [Show full text]
  • Surgical Treatment
    Arch Dis Child: first published as 10.1136/adc.58.2.137 on 1 February 1983. Downloaded from Archives of Disease in Childhood, 1983, 58, 137-141 Congenital heart disease in the neonate: results of surgical treatment E L BOVE, C BULL, J STARK, M DE LEVAL, F J MACARTNEY, AND J F N TAYLOR Thoracic Unit, The Hospitalfor Sick Children, London SUMMARY All 212 neonates undergoing cardiac surgery at this hospital during the 5-year period from 1976 to 1980 inclusive were reviewed. Forty required open heart surgery with 23 (57%) deaths. One hundred and seventy-four neonates underwent non-bypass procedures and could be divided into three groups: group 1 (82 patients) had inadequate pulmonary blood flow, group 2 (33 patients) had increased pulmonary blood flow or inadequate mixing, and group 3 (59 patients) had coarctation of the aorta, alone or with associated lesions. Forty-four (25 %) of the neonates undergoing non- bypass procedures died. Two required bypass surgery later in the first month of life. Metabolic acidosis and the need for preoperative respiratory support were appreciably greater in non-surviving patients. The spectrum of diagnoses encountered and types of operative procedures performed are analysed. Refinements in the surgical treatment of congenital Bypass procedures. Forty patients underwent pro- heart disease in the neonate continue to evolve. cedures involving cardiopulmonary bypass. Neonates copyright. Previous reports of cardiac surgery in the newborn constitute only 3-5 % of our patients undergoing have shown small numbers of patients and a high such operations as the procedures were undertaken operative mortality.1-35-8 The form of treatment only when both the cardiologist and surgeon caring chosen depends on the complexity of the cardiac for the patient felt that survival was unlikely without anomaly as well as the overall condition of the open heart surgery.
    [Show full text]
  • CARDIOPLEGIA SOLUTION a (Solution)
    NEW ZEALAND DATA SHEET 1 CARDIOPLEGIA SOLUTION A (solution) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1000mL contains the following active substances: Sodium chloride B.P. 6.43g Potassium chloride B.P. 1.19g Magnesium chloride hexahydrate B.P. 3.25g Calcium chloride dihydrate B.P. 176mg The mixture contains the following ions in 1000mL: Sodium 110mmol Magnesium 16mmol Chloride 160mmol Potassium 16mmol Calcium 1.2mmol For the full list of excipients, see Section 6.1. 3 PHARMACEUTICAL FORM Solution. Cardioplegia Solution A is a sterile, non‐pyrogenic solution for cardiac perfusion in a Viaflex bag. It is used to induce cardiac stasis and to protect the myocardium during open‐heart surgery. Cardioplegia Solution A is an isotonic crystalloid solution based on extracellular fluid ionic concentrations. Approximate osmolality is 275mOsm/kg and approximate pH is 3.7. Cardioplegia Solution A requires the aseptic addition of 10mL Sodium Bicarbonate 8.4% w/v Injection B.P. prior to use to adjust the pH to 7.4 ‐ 7.8. Following pH adjustment the total sodium ionic concentration is 120mmol/L. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Following pH adjustment with 10mL of Sodium Bicarbonate 8.4% w/v Injection B.P., Cardioplegia Solution A is used in combination with ischaemia and hypothermia to induce cardiac arrest during open heart surgery and to preserve the myocardium during asystole. 4.2 Dose and method of administration It is important that an appropriate dose of Cardioplegia Solution A is used to ensure that all areas of the myocardium are cooled evenly, especially those areas distal to arterial obstruction in patients with coronary‐artery disease.
    [Show full text]
  • Macdonald N Phd Final 130919
    Barriers to the Use of Goal Directed Therapy in a High Risk Surgical Patient Group A thesis submitted in fulfilment of the requirements of the degree of Doctor of Philosophy Neil MacDonald William Harvey Research Institute Barts and the London School of Medicine and Dentistry Queen Mary University of London 1 DECLARATION I, Neil MacDonald, confirm that the research included within this thesis is my own work or that where it has been carried out in collaboration with, or supported by, others that this is duly acknowledged below, and my contribution indicated. The work in chapter three is a result of large collaborative project and my contribution is outlined in chapter two. Previously published material is also acknowledged below. I attest that I have exercised reasonable care to ensure that the work is original, and does not to the best of my knowledge break any UK law, infringe any third party’s copyright or other Intellectual Property Right, or contain any confidential material. I accept that the College has the right to use plagiarism detection software to check the electronic version of the thesis. I confirm that this thesis has not been previously submitted for the award of a degree by this or any other university. The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author. Neil MacDonald 2 LIST OF COLLABORATION AND PUBLICATIONS Rupert M. Pearse, David A. Harrison, Neil MacDonald, Michael A. Gillies, Mark Blunt et al for the OPTIMISE study group.
    [Show full text]
  • Complete Draft Code Set Table of Contents
    Draft 2012 Procedural Coding System ICD~10~PCS Complete Draft Code Set Table of Contents Introduction . 1 Eye 080–08Y . 75 The ICD-10 Procedure Coding System (ICD-10-PCS) . 1 Ear Nose and Sinus 090–09W . 86 Introduction . 1 Respiratory System 0B1–0BY . 99 General Development Principles . 1 Mouth and Throat 0C0–0CX . 112 ICD-10-PCS Structure . .. 1 Gastrointestinal System 0D1–0DY . 123 ICD-10-PCS Format . 1 Hepatobiliary System and Pancreas 0F1–0FY . 141 Medical and Surgical Section (0) . 2 Endocrine System 0G2–0GW . 150 Obstetrics Section . 5 Skin and Breast 0H0–0HY . 155 Placement Section . 5 Subcutaneous Tissue and Fascia 0J0–0JX . .166 Administration Section . 6 Muscles 0K2–0KX . 181 Measurement and Monitoring Section . 6 Tendons 0L2–0LX . 189 Extracorporeal Assistance and Performance Section . 7 Bursae and Ligaments 0M2–0MX . .197 Extracorporeal Therapies Section . 7 Head and Facial Bones 0N2–0NW . 207 Osteopathic Section . 7 Upper Bones 0P2–0PW . 217 Other Procedures Section . 8 Lower Bones 0Q2–0QW . 227 Chiropractic Section . 8 Upper Joints 0R2–0RW . 237 Imaging Section . 8 Lower Joints 0S2–0SW . 249 Nuclear Medicine Section . 9 Urinary System 0T1–0TY . 262 Radiation Oncology Section . 9 Female Reproductive System 0U1–0UY . 272 Physical Rehabilitation and Diagnostic Audiology Male Reproductive System 0V1–0VW . 284 Section . 10 Anatomical Regions, General 0W0–0WW . 295 Mental Health Section . 10 Anatomical Regions, Upper Extremities 0X0–0XX . 303 Substance Abuse Treatment Section . 10 Anatomical Regions, Lower Extremities 0Y0–0YR . 309 Modifications to ICD-10-PCS . 10 Obstetrics 102–10Y . 315 Number of Codes in ICD-10-PCS . 11 Placement, Anatomical Regions 2W0–2W6 .
    [Show full text]
  • Icd-9-Cm (2010)
    ICD-9-CM (2010) PROCEDURE CODE LONG DESCRIPTION SHORT DESCRIPTION 0001 Therapeutic ultrasound of vessels of head and neck Ther ult head & neck ves 0002 Therapeutic ultrasound of heart Ther ultrasound of heart 0003 Therapeutic ultrasound of peripheral vascular vessels Ther ult peripheral ves 0009 Other therapeutic ultrasound Other therapeutic ultsnd 0010 Implantation of chemotherapeutic agent Implant chemothera agent 0011 Infusion of drotrecogin alfa (activated) Infus drotrecogin alfa 0012 Administration of inhaled nitric oxide Adm inhal nitric oxide 0013 Injection or infusion of nesiritide Inject/infus nesiritide 0014 Injection or infusion of oxazolidinone class of antibiotics Injection oxazolidinone 0015 High-dose infusion interleukin-2 [IL-2] High-dose infusion IL-2 0016 Pressurized treatment of venous bypass graft [conduit] with pharmaceutical substance Pressurized treat graft 0017 Infusion of vasopressor agent Infusion of vasopressor 0018 Infusion of immunosuppressive antibody therapy Infus immunosup antibody 0019 Disruption of blood brain barrier via infusion [BBBD] BBBD via infusion 0021 Intravascular imaging of extracranial cerebral vessels IVUS extracran cereb ves 0022 Intravascular imaging of intrathoracic vessels IVUS intrathoracic ves 0023 Intravascular imaging of peripheral vessels IVUS peripheral vessels 0024 Intravascular imaging of coronary vessels IVUS coronary vessels 0025 Intravascular imaging of renal vessels IVUS renal vessels 0028 Intravascular imaging, other specified vessel(s) Intravascul imaging NEC 0029 Intravascular
    [Show full text]
  • Cardioplegia Versus Intermittent Ischaemic Arrest in Coronary Bypass Surgery
    Thorax: first published as 10.1136/thx.37.12.887 on 1 December 1982. Downloaded from Thorax 1982;37:887-892 Cardioplegia versus intermittent ischaemic arrest in coronary bypass surgery JR PEPPER, E LOCKEY, S CANKOVIC-DARRACOTT, MV BRAIMBRIDGE From the London Chest Hospital and Rayne Institute, St Thomas's Hospital, London ABSTRACT No definitive method of myocardial preservation has been established and conclusions based on experimental data may not be applicable to patients witq coronary artery disease. Fifty patients undergoing coronary bypass grafting were randomly assigned to one of two groups for myocardial preservation. In group A cold cardioplegia with external cardiac cooling was used and in group B ischaemic arrest with mild systemic cooling to 32°C. Myocardial preservation was assessed by analysis of enzymes specific to the heart, left ventricular biopsy, and electrocardiography. Equal protection of the myocardium was provided in both groups but the mean cross-clamp time in group A was significantly longer than in group B. This implies that cardioplegia confers greater protection than intermittent ischaemic arrest. Most cardiac surgeons use some form of cold excluded because interpretation of the perioperative cardioplegia to protect the heart during coronary ECG would not be standardised. All patients bypass grafting, but a minority prefer intermittent received the same anaesthetic regimen and were copyright. ischaemic arrest and obtain excellent clinical results. operated on by one surgeon. The characteristics of Recent prospective randomised studies comparing the two groups were similar (table 1), but cross- ischaemic arrest and cold cardioplegia have used clamp time and perfusion time were longer in the topical hypothermia in the ischaemic group and group receiving cardioplegia.
    [Show full text]
  • Higher Institutional Volume Reduces Mortality in Reoperative Proximal Thoracic Aortic Surgery
    Published online: 2020-11-05 THIEME Original Research Article 59 Higher Institutional Volume Reduces Mortality in Reoperative Proximal Thoracic Aortic Surgery Nicholas J. Shea, MD, MS1 Alex M. D’Angelo, MD1 Antonio R. Polanco, MD1 Philip Allen, BS1 Joseph E. Sanchez, BS1 Paul Kurlansky, MD1 Virendra I. Patel, MD, MPH1 Hiroo Takayama, MD, PhD1 1 Department of Surgery, New York-Presbyterian Hospital, Columbia Address for correspondence Hiroo Takayama, MD, PhD, 177 Ft University Aortic Surgery Center, Columbia University Irving Medical Washington Avenue, MHB 7GN 435, New York, NY 10032 Center,NewYork,NewYork (e-mail: [email protected]). AORTA 2020;8:59–65. Abstract Objective This study aims to determine the impact of institutional volume on mortality in reoperative proximal thoracic aortic surgery patients using national outcomes data. Methods The Nationwide Inpatient Sample was queried from 1998 to 2011 for patients with diagnoses of thoracic aneurysm and/or dissection who underwent open mediastinal repair. A total of 103,860 patients were identified. A total of 1,430 patients had prior cardiac surgery. Patients were further stratified into groups by institutional aortic volume: low (<12 cases/year), medium (12–39 cases/year), and high (40þ cases/year) volume. Multivariable risk-adjusted analysis accounting for emergent status and aortic dissection among other factors was performed to determine the impact of institutional volume on mortality. Results Overall mortality was 12% in the reoperative population. When the redo cohort was divided into tertiles, high-volume group had a 5% operative mortality compared with 9 and 15% for the medium- and low-volume groups, respectively.
    [Show full text]
  • Fate of the Coronary Ostial and Distal Aortic Anastomoses After Modified Bentall’S Operation (UKC’S Modification)
    Chowdhury UK, George N, Singh S, Hasija S, Sankhyan LK, Sharma S, Pandey NN, Sengupta S, Kalaivani M. Fate of the Coronary Ostial and Distal Aortic Anastomoses after Modified Bentall’s Operation (UKC’s Modification). J Surg & Journal of Surgical Tech.2020;2(1):11-20 Surgery and Surgical Technology Original Research Article Open Access Fate of the Coronary Ostial and Distal Aortic Anastomoses after Modified Bentall’s Operation (UKC’s Modification) Ujjwal K. Chowdhury1*, Niwin George1, Sukhjeet Singh1, Suruchi Hasija2, Lakshmikumari Sankhyan1, Srikant Sharma1, Niraj Nirmal Pandey3, Sanjoy Sengupta1, Mani Kalaivani4 1Departments of Cardiothoracic and Vascular Surgery, All India Institute of Medical Sciences, New Delhi, India. 2Department of Cardiac Anaesthesia, All India Institute of Medical Sciences, New Delhi, India. 3Department of Cardiac Radiology ,All India Institute of Medical Sciences, New Delhi, India. 4Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India. Article Info Article Notes Received: May 04, 2020 Accepted: June 13, 2020 *Correspondence: Dr. Ujjwal Kumar Chowdhury, M.Ch, Diplomate NB, Professor, Department of Cardiothoracic and Vascular Surgery, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029, India; Telephone No: 91-11-26594835; Fax No: 91-11- 26588663, 26588641; Email: [email protected], [email protected]; Orcid ID: http://orcid.org/0000-0002-1672-1502. ©2020 Chowdhury UK. This article is distributed under the terms of the Creative Commons Attribution
    [Show full text]
  • Medtronic Structural Heart ICD-10 Coding for Hospitals
    Medtronic Structural Heart ICD-10 Coding for Hospitals Linda Holtzman RHIA, CCS, CCS-P, CPC,COC Clarity Coding January 2016 Disclaimer Reimbursement information provided by Medtronic is for illustrative purposes only and does not constitute legal advice. Information provided is gathered from third party sources and is subject to change without notice due to frequently changing laws, rules and regulations. Medtronic makes no guarantee that the use of this information will prevent differences of opinion or disputes with Medicare or other third party payers as to the correct form of billing or the amount that will be paid to providers of service. The provider of service has the responsibility to determine medical necessity and to submit appropriate codes and charges for care provided. Please contact your local payers, reimbursement specialists and/or legal counsel for interpretation of coding, coverage, and payment policies. Medtronic does not promote the use of its products outside FDA-approved labeling. 2 Topics Background and Framework ICD-10-CM Diagnosis Codes ICD-10-PCS Procedure Codes DRG Impact Appendix : Key Resources Questions Attachment : Diagnosis Code Crosswalks 3 Background and Framework 4 Effective Date ICD-10 went into effect October 1, 2015. Use of ICD-10 in the United States was formally proposed in August 2008 and finalized in January 2009. Implementation of ICD-10 was initially scheduled for October 2013 and has been postponed twice since then. ICD-10 is effective by date of discharge, not by date of admission. ICD-10-CM for diagnosis codes and ICD-10-PCS for procedure codes go into effect together on the same date.
    [Show full text]